Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study

OBJECTIVE: Immune checkpoint inhibitors (ICIs) have recently been increasingly used in cancer treatment, whereas their clinical application in biliary tract cancer (BTC) patients is uncommon. This study aimed to evaluate the efficacy and safety of ICIs plus capecitabine and oxaliplatin (CAPOX) in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jie, Guo, Yongzhong, Ding, Wenzhou, Han, Guoyong, Jiang, Chuanwei, Yang, Chao, Hu, Yuanchang, Zhang, Long, Wu, Chen, Ni, Ming, Kong, Xiangyi, Huang, Tian, Zhang, Chuanyong, Xia, Yongxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582263/
https://www.ncbi.nlm.nih.gov/pubmed/36276134
http://dx.doi.org/10.3389/fonc.2022.965711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582263/
https://www.ncbi.nlm.nih.gov/pubmed/36276134
http://dx.doi.org/10.3389/fonc.2022.965711

Ejemplares similares